AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko, Kirill A. Dmitriev, Natalia V. Vostokova, Valeria N. Azarova, Andrew A. Blinow, Alina N. Egorova, Ivan G. Gordeev, Alexey P. Ilin, Ruben N. Karapetian, Dmitry V. Kravchenko, Nikita V. Lomakin, Elena A. Merkulova, Natalia A. Papazova, Elena P. Pavlikova, Nikolay P. Savchuk, Elena N. Simakina, Tagir A. Sitdekov, Elena A. Smolyarchuk, Elena G. Tikhomolova, Elena V. Yakubova, Alexandre V. Ivachtchenko
doi: https://doi.org/10.1101/2020.07.26.20154724

Data Availability

N/A

Back to top
Posted August 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko, Kirill A. Dmitriev, Natalia V. Vostokova, Valeria N. Azarova, Andrew A. Blinow, Alina N. Egorova, Ivan G. Gordeev, Alexey P. Ilin, Ruben N. Karapetian, Dmitry V. Kravchenko, Nikita V. Lomakin, Elena A. Merkulova, Natalia A. Papazova, Elena P. Pavlikova, Nikolay P. Savchuk, Elena N. Simakina, Tagir A. Sitdekov, Elena A. Smolyarchuk, Elena G. Tikhomolova, Elena V. Yakubova, Alexandre V. Ivachtchenko
medRxiv 2020.07.26.20154724; doi: https://doi.org/10.1101/2020.07.26.20154724
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area